drugset / Trial / NCT04645966

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

NCT04645966

Phase 2 Terminated 326 enrolled Pfizer
RandomizedFactorialDouble-blindPrevention

Summary

The aim of the study is to describe the safety, tolerability, and immunogenicity of MenABCWY in healthy infants 2 and 6 months of age.

Timeline

Start
2020-11-26
Primary completion
2022-09-15
Completion
2022-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Bexsero Vaccine
Subject Bivalent rLP2086 Vaccine 60 ug
Subject Bivalent rLP2086 Vaccine 120 ug
Subject MenABCWY Vaccine
Subject Menveo Vaccine
Background Acetaminophen Small molecule